Guest Editor:

Prof. Dr. H. Miles Prince
Centre for Blood Cell Therapies, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A\Beckett St Melbourne 8006, Victoria, Australia
miles.prince@petermac.org

Deadline for manuscript submissions: closed (31 July 2011)

Message from the Guest Editor

Dear Colleagues,

Histone deacetylase inhibitors are clearly effective therapeutic tools in the treatment of cancers, particularly haematological malignancies. The purpose of this special issue is to provide the reader with a focused review of on the current place of HDACi as a therapy, particularly in blood cancers. We hope to provide a broad overview of the rationale behind their use, with specific papers focusing on diseases where they clearly have biological effects - NHL, Hodgkin disease, myeloid malignancies. Finally we hope to have two separate papers examining mechanisms of resistance and common toxicities.

I hope you will be able to contribute to what I see will be a valuable compendium of insightful reviews in this very topical subject.

Prof. Dr. H. Miles Prince
Guest Editors

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.


Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 27 days after submission; acceptance to publication is undertaken in 6 days (median values for papers published in this journal in 2016).